HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

September 1, 2021

Study Completion Date

June 8, 2022

Conditions
Hepatitis CRenal Insufficiency, ChronicDisorder of Transplanted Kidney
Interventions
DRUG

Post-transplant Grazoprevir and Elbasvir

Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)

Trial Locations (1)

21201

University of Maryland Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT02902120 - HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant | Biotech Hunter | Biotech Hunter